EPS for Eagle Pharmaceuticals (EGRX) Expected At $0.53, VIADERMA (VDRM) SI Increased By 95.94%

July 18, 2017 - By Dolores Ford

Analysts expect Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to report $0.53 EPS on August, 8.They anticipate $0.27 EPS change or 33.75% from last quarter’s $0.8 EPS. EGRX’s profit would be $8.04M giving it 36.08 P/E if the $0.53 EPS is correct. After having $1.42 EPS previously, Eagle Pharmaceuticals Inc’s analysts see -62.68% EPS growth. The stock increased 1.02% or $0.77 during the last trading session, reaching $76.5. About shares traded. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has risen 79.40% since July 18, 2016 and is uptrending. It has outperformed by 62.70% the S&P500.

VIADERMA INCORPORATED (OTCMKTS:VDRM) had an increase of 95.94% in short interest. VDRM’s SI was 198,100 shares in July as released by FINRA. Its up 95.94% from 101,100 shares previously. The stock increased 1.29% or $0.0002 on July 17, reaching $0.0172. About 474,428 shares traded. Viaderma Inc (OTCMKTS:VDRM) has 0.00% since July 18, 2016 and is . It has underperformed by 16.70% the S&P500.

ViaDerma, Inc. is a pharmaceutical company focused on bringing new products to the pharmaceutical industry through research and development. The company has market cap of $6.32 million. The Firm licenses and sells products in fields of medicine ranging from infectious diseases to stem-cell therapy. It currently has negative earnings. The Company’s products are applied topically using a delivery system technology.

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has market cap of $1.16 billion. The Firm focuses on developing and commercializing injectable products in the critical care and oncology areas. It has a 11.82 P/E ratio. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Eagle Pharma had 12 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) earned “Neutral” rating by Mizuho on Wednesday, November 16. Mizuho downgraded Eagle Pharmaceuticals Inc (NASDAQ:EGRX) rating on Monday, January 9. Mizuho has “Underperform” rating and $64 target. The firm earned “Neutral” rating on Monday, June 20 by Mizuho. The rating was maintained by RBC Capital Markets with “Outperform” on Tuesday, May 10. RBC Capital Markets maintained the stock with “Outperform” rating in Thursday, November 3 report. Mizuho initiated the stock with “Buy” rating in Wednesday, December 9 report. William Blair maintained the shares of EGRX in report on Wednesday, November 2 with “Outperform” rating. The stock has “Overweight” rating by Piper Jaffray on Wednesday, July 29. The company was upgraded on Thursday, November 3 by Mizuho. On Friday, February 26 the stock rating was maintained by Mizuho with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: